Peter E. Boyd - 09 Mar 2023 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: SVP, Information Technology, Human Resources and Communications
Issuer ticker: AQST
Reported as of: 09 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Mar 2023, 14:07:58 UTC
Prior SEC filing: 08 Nov 2022
Next SEC filing: 05 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Lori Braender, as Attorney-In-Fact

Key filing fact

Peter E. Boyd filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 09 Mar 2023.

Key facts

This page summarizes Peter E. Boyd's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Mar 2023, 14:07.

Change

Previous filing in this sequence was filed on 08 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Award

Transaction value: $0
Shares: +100,000
Change %: +168%
Price: $0.000000
Shares after: 159,532
Date: 09 Mar 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC remarks

SVP, Information Technology, Human Resources and Communications